GLP-1 medications work through several complementary mechanisms: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood sugar levels Suppressing glucagon release , thereby reducing hepatic glucose production Slowing gastric emptying , which prolongs satiety and reduces appetite Acting on appetite centres in the brain , leading to reduced caloric intake and weight loss Commonly prescribed GLP-1 receptor agonists available in the UK include semaglutide (Ozempic, Wegovy, Rybelsus [oral form]), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon)
Hypoglycemia, or low blood sugar, can cause shakiness, sweating, confusion, weakness, or fainting
The research team noted that the reduction in body weight was not related to any nausea or vomiting reported by the patients [2]
J1815 sits within the broader J-code range (J0000-J9999), which covers drugs administered other than by the oral method
(2006) Endocrine n=20 Trial demonstrating ipamorelin improved insulin sensitivity, lipid profile, and reduced inflammation